Press Room

AAPS 2016

Start
Sunday, November 13, 2016 - 00:00
End
Thursday, November 17, 2016 - 00:00
Location: Denver, United States
Booth Number: 1627
spray drying pharmaceutical industry USA | Hovione

Hovione will be present at the 2016 AAPS Annual Meeting in the Colorado Convention Center in Denver.

A set of seven (7) posters will be exhibited in the poster session. If you are attending AAPS, look for Hovione in the poster session and meet with one of our experts.

 

HOVIONE POSTERS

Aerodynamic Performance of DPIs versus Process Efficiency: A Necessary Compromise

Filipa M. Maia, Maria Palha, Isabel S. Lopes, Filipe Neves

 

Watch Poster Video at AAPS by Márcio Temtem:

 

Innovative Spray Drying Process for Microencapsulation of Dexamethasone for Controlled Ocular Release

Filipa M. Maia1 , Maria Paiva1 , R. Yamamoto2 , T. Cavanagh2 , Filipe Neves1

1 Hovione PharmaScience S.A., 2 Precision Ocular Ltd.

Bulk Properties Impact on the Performance of Amorphous Solid Dispersions 

Iris Duarte, Rui Ferreira, João Vicente

The Impact of Reprocessing on Typical Physicochemical Attributes and Particle Properties of Spray Dried Kollidon® VA64

Rui Ferreira, Iris Duarte, Márcio Temtem

Particle Engineering through Solvent Precipitation: Batch vs Continuous Operation 

Tiago Porfirio, Iris Duarte, João Vicente

Compaction Simulation of an Amorphous Spray Dried Dispersion

João Henriques, Márcio Temtem, Conrad Winters

Modeling Droplet Dynamic and Thermal Profile of Spray Congealing Technology

Inês Matos, Hugo Lisboa, João Henriques, Márcio Temtem

 

Contact us if you would like to schedule a meeting or to find more about the Hovione posters at AAPS.

Schedule a meeting button | Hovione

 

Our colleague, Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

       

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026